J&J’s Tremfya shows fistula remission in Crohn’s subgroups

Johnson & Johnson (JNJ) reported three-year data from its Phase 3 GALAXI 2 and 3 studies on TREMFYA for Crohn's disease. 94% and 91% of patients achieved clinical remission with 100 mg and 200 mg doses, respectively. 52% and 61% achieved endoscopic remission. 74% remained on treatment for three years. Data was presented at the American College of Gastroenterology 2026 Annual Scientific Meeting.

Johnson & Johnson reported 3-year data from GALAXI 2 and 3 studies showing TREMFYA achieved up to 94% clinical remission and 61% endoscopic remission in Crohn's patients. 88% maintained 90-day corticosteroid-free remission. Safety profile remained consistent. Data presented at ACG 2026.

Johnson & Johnson announced Phase 3 data showing TREMFYA (guselkumab) achieved consistent combined fistula remission rates in Crohn's disease patients with perianal fistula, including difficult-to-treat subgroups. Remission rates were 28% and 27% for two dosing groups vs. 10% for placebo. Results were presented at the ACG 2026 Annual Scientific Meeting.

Johnson & Johnson's long-term study on TREMFYA for Crohn's disease shows 94% clinical remission and 61% endoscopic remission after three years. 88% of patients achieved 90-day corticosteroid-free remission. The data, from GALAXI 2 and 3 studies, demonstrate sustained outcomes with two dosing regimens. TREMFYA is the only approved dual-acting monoclonal antibody for inflammatory bowel disease.

Johnson & Johnson's drug TREMFYA showed consistent efficacy in treating Crohn's disease with perianal fistula across key patient subgroups, including those with prior biologic exposure. Phase 3 trial results showed 28% combined fistula remission rates. The drug is approved for Crohn's and other inflammatory conditions.

Johnson & Johnson (JNJ) reported that its oral psoriasis drug, ICOTYDE, maintained skin clearance through 112 weeks in a Phase 3 study, with 89% of genital psoriasis patients and 60% of scalp psoriasis patients achieving complete clearance. The study, presented at a dermatology congress, showed improved outcomes in difficult-to-manage areas, with no new safety concerns identified. JNJ aims to differentiate ICOTYDE in the psoriasis treatment market with its oral delivery.